• EIP Pharma Initiates Neflamapimod Study americanpharmaceuticalreview
    July 10, 2019
    EIP Pharma announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington's disease, a rare, genetically inherited disease that causes the nerve cells of ...
  • NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study prnasia
    July 05, 2019
    NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333 ...
PharmaSources Customer Service